May 7th 2024
New data from a World Health Organization (WHO) repository illustrates the treatment challenges during the acute phase of the pandemic.
The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.
Read More
FDA Approves Sulbactam-Durlobactam for Bacterial Pneumonia
May 23rd 2023The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.
Read More
Preparing for AUR Reporting Mandates to Capitalize on Quality Reimbursement
May 15th 2023The mandatory reporting of Antimicrobial Use and Resistance (AUR) by hospitals participating in the CMS Medicare Promoting Interoperability Program beginning next year is a important strategy in curbing the overuse of antibiotics.
Read More
CDC, FDA Investigating Eye Drops Linked to Bacterial Infection
April 3rd 2023According to the CDC, the outbreak strain of carbapenem-resistant Pseudomonas aeruginosa with Verona integron-mediated metallo-β-lactamase and Guiana extended-spectrum-β-lactamase (VIM-GES-CRPA), has never been reported in the US prior to this outbreak.
Read More